别名 Azoreductase、DHQU、DIA4 + [13] |
简介 Flavin-containing quinone reductase that catalyzes two-electron reduction of quinones to hydroquinones using either NADH or NADPH as electron donors. In a ping-pong kinetic mechanism, the electrons are sequentially transferred from NAD(P)H to flavin cofactor and then from reduced flavin to the quinone, bypassing the formation of semiquinone and reactive oxygen species (PubMed:8999809, PubMed:9271353) (By similarity). Regulates cellular redox state primarily through quinone detoxification. Reduces components of plasma membrane redox system such as coenzyme Q and vitamin quinones, producing antioxidant hydroquinone forms. In the process may function as superoxide scavenger to prevent hydroquinone oxidation and facilitate excretion (PubMed:8999809, PubMed:9271353, PubMed:15102952). Alternatively, can activate quinones and their derivatives by generating redox reactive hydroquinones with DNA cross-linking antitumor potential (PubMed:8999809). Acts as a gatekeeper of the core 20S proteasome known to degrade proteins with unstructured regions. Upon oxidative stress, interacts with tumor suppressors TP53 and TP73 in a NADH-dependent way and inhibits their ubiquitin-independent degradation by the 20S proteasome (PubMed:15687255, PubMed:28291250). |
作用机制 Mcl-1抑制剂 [+2] |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2024-09-27 |
作用机制 NQO1抑制剂 [+2] |
在研机构- |
原研机构- |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 NAD+调节剂 [+1] |
在研机构 |
在研适应症 |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-08-09 |
申办/合作机构- |
开始日期2022-12-13 |
申办/合作机构 |
开始日期2022-10-30 |
申办/合作机构- |